NDAORALTABLET
Approved
May 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXIBOLIN (ethylestrenol) is an oral anabolic steroid approved by Merck & Co. in 1964. It is a synthetic derivative with anabolic properties historically used to promote protein synthesis and tissue growth. The drug's mechanism of action involves androgenic and anabolic receptor activation.
LOE Approaching
With LOE approaching and minimal linked job activity, this legacy product faces significant commercial headwinds with likely limited team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings signal minimal active investment in MAXIBOLIN; roles are likely support-only or phase-out focused. Career growth on this product is limited; assignment here typically reflects portfolio maintenance rather than career advancement.
Brand Manager (legacy)Compliance Specialist
Worked on MAXIBOLIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.